The Pharma Data

DECEMBER 13, 2020

.–( BUSINESS WIRE )– EdiGene, Inc. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. He received his B.S. He received his B.S.

Business Development 40

Business Development Development Gene Editing In-Vivo 40

Drug Discovery World

APRIL 17, 2024

DS: You say on your website that your approach is applicable to any disease where increasing protein expression is beneficial. What diseases are you currently targeting? JMB: Hundreds of genetic diseases involve a missing or deficient protein and/or enzyme. Can you give some examples? What’s in the pipeline?

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

Pharmaceutical Technology

JULY 29, 2022

In order to find the specific RNA sequences for a genetic disease, the biotech is using an AI- and machine learning-based approach. In order to achieve these plans, CAMP 4’s CEO, Josh Mandel-Brehm stated the company will prioritise raising capital through partnerships and business development. Future Possibilities.

RNA 245

RNA Gene Expression Gene Gene Therapy 245

Drug Discovery World

JANUARY 30, 2024

“Dr Naldini open new doors for cures for otherwise untreatable genetic diseases with the full impact of his work still untapped”, she said. Developing more efficient and affordable alternatives is key. Developing value-based payment models that consider long-term benefits could improve access.

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

Pharmaceutical Technology

JUNE 19, 2023

Pharmaceutical companies are putting their trust in the immense potential this new generation of medicine has for treating individuals with rare genetic diseases, which currently affect an estimated 280 million patients worldwide. Cell and gene therapies are not your typical clinical supply chain.

Gene Therapy 130

Gene Therapy Gene Packaging Packaging 130

Drug Discovery World

AUGUST 28, 2023

We have a combination of talented and motivated young scientists along with experienced industry experts who have been through the process of drug research and development. Could it be possible to prevent genetic diseases? DS: What’s next for the company’s pipeline? LinkedIn profile.

Genetics 52

Genetics Protein Genetic Disease Clinical Trials 52

The Pharma Data

DECEMBER 8, 2020

AbCellera’s AI-powered antibody discovery platform speeds the otherwise lengthy and grueling process by analyzing the database of natural immune systems to find antibodies that can be developed into drugs. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost. Sigilon Therapeutics

RNA 52

RNA Antibody Life Science Protein 52